Two independent players in the radiopharma sector, Curium and Lantheus, have agreed to merge to create a combined company with annual revenues estimated at around $2.1 billion. The combined entity will span the full nuclear medicine value chain, from isotope production and manufacturing to diagnostic imaging and targeted radionuclide therapy. Lantheus' main products are Pylarify (piflufolastat), used to detect prostate cancer, and Definity (perflutren) for heart imaging, which accounted for most of its $1.54 billion in revenues last year. The target-based payments promised to its shareholders will come into play if global sales of prostate cancer diagnostics, Definity, and various neurology diagnostics pass agreed thresholds. Privately-held Curium, meanwhile, sells a range of radiopharma products including prostate cancer diagnostic Pylclari (piflufolastat F 18), generic SPECT brain imaging agent ioflupane I 123, and DetectNet (copper Cu 64 dotatate) for detecting neuroendocrine tumours (NETs).